Lanean...
The “rights” of precision drug development for Alzheimer’s disease
There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple diso...
Gorde:
| Argitaratua izan da: | Alzheimers Res Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717388/ https://ncbi.nlm.nih.gov/pubmed/31470905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0529-5 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|